eligibility_summary
Adults ≥18 with histologically confirmed advanced ESCC (unresectable/recurrent/metastatic) after platinum and anti-PD-1/PD-L1, measurable disease (RECIST 1.1), ECOG 0-1, tumor tissue for Trop-2, adequate blood counts, hepatic function, CrCl >=30, agree to contraception/compliance. Exclude: pregnancy, hypersensitivity, recent/unrecovered anticancer therapy, prior topo I, other active cancer, IBD/GI perf, serious infection, HIV, active HBV/HCV, CNS mets, adenocarcinoma (esophagus/GEJ).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drug/intervention: Sacituzumab govitecan (SG), an antibody–drug conjugate (ADC) delivering SN‑38, the active metabolite of irinotecan (a topoisomerase I inhibitor). Mechanism: A humanized anti–Trop‑2 monoclonal antibody binds Trop‑2 on ESCC cells, is internalized, and releases SN‑38 via a hydrolyzable linker, inhibiting topoisomerase I, inducing DNA damage, S‑phase arrest, and apoptosis, extracellular release can produce a bystander effect. Targets: Trop‑2–overexpressing esophageal squamous carcinoma cells, DNA topoisomerase I pathway in proliferating tumor cells. Trial: Phase II, single‑arm, SG 10 mg/kg IV on days 1 and 8 of a 21‑day cycle after platinum and anti‑PD‑1/PD‑L1 therapy, tumor tissue assessed for Trop‑2.